中度慢性活动性肝炎的长期随访
Long-term follow-up of chronic active hepatitis of moderate severity.
作者信息
De Groote J, Fevery J, Lepoutre L
出版信息
Gut. 1978 Jun;19(6):510-3. doi: 10.1136/gut.19.6.510.
Abstract
A group of patients with only moderately active chronic hepatitis has been studied. The follow-up was long (mean 87 months). All patients except one were treated with prednisone and/or azathioprine. Of the hepatitis B virus positive patients two-thirds developed cirrhosis between the second and fifth year of evolution, while in the hepatitis B negative group this occurred in less than one-third. The transition to cirrhosis was clinically silent. The patients were all allowed to do their normal work except in the terminal stages of cirrhosis. Five patients died of causes related to the disease: three patients with cirrhosis and hepatocellular carcinoma, one with gallbladder carcinoma, and one from bleeding varices. The high incidence of tumour, especially liver-cell carcinoma, may be due to a cumulative effect of the presence of hepatitis B virus, cirrhotic transformation, and immuno-suppression. The other patients are currently in apparently good health.
摘要
对一组仅有中度活动性慢性肝炎的患者进行了研究。随访时间较长（平均87个月）。除1例患者外，所有患者均接受了泼尼松和/或硫唑嘌呤治疗。在乙肝病毒阳性患者中，三分之二在病程的第二年至第五年发展为肝硬化，而在乙肝阴性组中，这一比例不到三分之一。向肝硬化的转变在临床上并无症状。除了肝硬化终末期患者外，所有患者都能正常工作。5例患者死于与疾病相关的原因：3例肝硬化合并肝细胞癌患者，1例胆囊癌患者，1例死于曲张静脉出血。肿瘤的高发病率，尤其是肝细胞癌，可能是由于乙肝病毒的存在、肝硬化转变和免疫抑制的累积效应。其他患者目前健康状况明显良好。
相似文献
1
Long-term follow-up of chronic active hepatitis of moderate severity.中度慢性活动性肝炎的长期随访
Gut. 1978 Jun;19(6):510-3. doi: 10.1136/gut.19.6.510.
2
[Immunosuppressive therapy of chronic aggressive hepatitis and primary biliary cirrhosis].
Med Klin. 1972 Apr 14;67(15):527-34.
3
[Immediate and long-term effects of therapeutic immunodepression in active chronic hepatitis. Prospective study of the action of prednisone and azathioprine].[治疗性免疫抑制在活动性慢性肝炎中的即刻和长期效应。泼尼松和硫唑嘌呤作用的前瞻性研究]
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna. 1981 Jul-Aug;33(4):371-82.
4
[Long-term clinical observations of chronic active hepatitis HBsAg (+)].慢性活动性乙型肝炎表面抗原阳性的长期临床观察
Pol Arch Med Wewn. 1992 Oct;88(4):250-5.
5
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.慢性乙型肝炎患者长期肝硬化和肝细胞癌风险的预测模型：整合宿主和病毒特征的风险评分。
Hepatology. 2013 Aug;58(2):546-54. doi: 10.1002/hep.26385.
6
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.核苷（酸）类似物在无或小食管静脉曲张代偿性乙型肝炎肝硬化患者中的长期获益：一项 12 年的前瞻性队列研究。
J Hepatol. 2015 Nov;63(5):1118-25. doi: 10.1016/j.jhep.2015.06.006. Epub 2015 Jun 19.
7
[Long-term results of immunosuppressive treatment of chronic aggressive hepatitis (author's transl)].
Dtsch Med Wochenschr. 1978 Dec 15;103(50):1989-93. doi: 10.1055/s-0028-1129382.
8
[Attempted classification, course and elements of prognosis of chronic hepatitis. Preliminary results of a study of 100 cases].
Ann Med Interne (Paris). 1972 Feb;123(2):107-17.
9
[Immunosuppressive treatment of HBs-antigen positive and negative chronic-active hepatitis (author's transl)].
Dtsch Med Wochenschr. 1978 May 26;103(21):887-92. doi: 10.1055/s-0028-1104782.
10
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.抗病毒治疗不能预防拉米夫定单药起始治疗的 HBeAg 阴性代偿期乙型肝炎肝硬化患者发生肝癌：全国性 HEPNET. 希腊队列研究结果。
Gut. 2011 Aug;60(8):1109-16. doi: 10.1136/gut.2010.221846. Epub 2011 Jan 26.
引用本文的文献
1
Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease.自身免疫性肝病患者肝脏纤维化的点剪切波弹性成像（pSWE）诊断性能。
PLoS One. 2019 Mar 11;14(3):e0212771. doi: 10.1371/journal.pone.0212771. eCollection 2019.
2
Suitability of the simplified autoimmune hepatitis score for the diagnosis of autoimmune hepatitis in a German cohort.简化自身免疫性肝炎评分在德国队列中用于自身免疫性肝炎诊断的适用性。
United European Gastroenterol J. 2018 Mar;6(2):247-254. doi: 10.1177/2050640617711632. Epub 2017 May 18.
3
Clinical usefulness of ursodeoxycholic acid for Japanese patients with autoimmune hepatitis.熊去氧胆酸对日本自身免疫性肝炎患者的临床效用。
World J Hepatol. 2017 Jan 8;9(1):57-63. doi: 10.4254/wjh.v9.i1.57.
4
Epidemiology and treatment of autoimmune hepatitis.自身免疫性肝炎的流行病学与治疗
Hepat Med. 2012 Mar 16;4:1-10. doi: 10.2147/HMER.S16321.
5
Treatment of autoimmune liver disease: current and future therapeutic options.自身免疫性肝病的治疗：当前和未来的治疗选择。
Ther Adv Chronic Dis. 2013 May;4(3):119-41. doi: 10.1177/2040622313478646.
6
Autoimmune hepatitis as a unique form of an autoimmune liver disease: immunological aspects and clinical overview.自身免疫性肝炎作为自身免疫性肝病的一种独特形式：免疫学方面及临床概述
Autoimmune Dis. 2012;2012:312817. doi: 10.1155/2012/312817. Epub 2012 Dec 12.
7
Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.预防拉米夫定用于预防乙型肝炎病毒母婴垂直传播的成本效益分析。
Pharmacoeconomics. 2011 Dec;29(12):1063-73. doi: 10.2165/11586470-000000000-00000.
8
Current status of therapy in autoimmune liver disease.自身免疫性肝病的治疗现状。
Therap Adv Gastroenterol. 2009 Jan;2(1):11-28. doi: 10.1177/1756283X08098966.
9
Difficult treatment decisions in autoimmune hepatitis.自身免疫性肝炎的治疗决策难题。
World J Gastroenterol. 2010 Feb 28;16(8):934-47. doi: 10.3748/wjg.v16.i8.934.
10
Non-classical phenotypes of autoimmune hepatitis and advances in diagnosis and treatment.自身免疫性肝炎的非经典表型及诊断与治疗进展
World J Gastroenterol. 2009 May 21;15(19):2314-28. doi: 10.3748/wjg.15.2314.
本文引用的文献
1
Protracted and recurrent forms of viral hepatitis.迁延性和复发性病毒性肝炎
Am J Dis Child. 1972 Apr;123(4):283-6. doi: 10.1001/archpedi.1972.02110100015006.
2
Active chronic hepatitis.活动性慢性肝炎
Am J Med. 1970 Apr;48(4):484-95. doi: 10.1016/0002-9343(70)90049-5.
3
Primary hepatoma in Uganda. A prospective clinical and epidemiologic study of forty-six patients.乌干达的原发性肝癌。对46例患者的前瞻性临床与流行病学研究。
Am J Med. 1969 May;46(5):794-802. doi: 10.1016/0002-9343(69)90030-8.
4
Hepatitis-associated antigen in chronic liver disease.
Lancet. 1970 Jul 11;1(7663):100. doi: 10.1016/s0140-6736(70)92672-3.
5
Hepatitis-associated antigen in chronic liver disease.慢性肝病中的肝炎相关抗原。
Lancet. 1969 Sep 20;2(7621):609-12. doi: 10.1016/s0140-6736(69)90324-9.
6
Australia antigen in acute and chronic liver disease.急慢性肝病中的澳大利亚抗原
Lancet. 1969 Jul 19;2(7612):117-21. doi: 10.1016/s0140-6736(69)92437-4.
7
A classification of chronic hepatitis.慢性肝炎的一种分类
Lancet. 1968 Sep 14;2(7568):626-8. doi: 10.1016/s0140-6736(68)90710-1.
8
Hepatitis-B-antigen in chronic liver diseases (author's transl).慢性肝病中的乙型肝炎抗原（作者译）
Med Klin. 1973 Nov 16;68(46):1503-10.
9
Detection of hepatitis-B antigen by radioimmunoassay in chronic liver disease and hepatocellular carcinoma in Great Britain.在英国，采用放射免疫分析法检测慢性肝病和肝细胞癌中的乙型肝炎抗原。
Lancet. 1973 Sep 29;2(7831):690-4. doi: 10.1016/s0140-6736(73)92534-8.
10
Chronic active hepatitis in children.
Am J Dig Dis. 1972 Jul;17(7):575-82. doi: 10.1007/BF02231742.
Zotero 插件